9month28day paragraph16Global Growth, Innovation and Leadership Summit 2023 & Frost & Sullivan Biotechnology Investment Sub-forum The Shanghai International Convention Center successfully concluded its operations, Sharley Dr. Wang Xin, Partner at WEN Global and President of Greater China, delivered a welcome speech at the conference.
Live video
The following are the key points of Dr. Wang Xin's speech:
With the intensification of aging, the healthcare industry faces both challenges and opportunities.
According to the data, as of2021At the end of the year, nationwide60The elderly population aged 60 and above reached2.67Yi, accounting for the total population18.9%;65The elderly population aged 60 and above reached2More than 100 million, accounting for the total population14.2%According to United Nations standards,65The proportion of people over [age] exceeds14%, it is already a society in deep aging.
As China enters an aging society, the number of elderly chronic disease patients is also increasing year by year, posing a huge challenge to the development of China's healthcare industry. However, challenges and opportunities coexist, and the future prospects for the healthcare industry are broad.
The digital and intelligent transformation of industries is the direction to be determined.
The new generation has seen black swans and grey rhinos becoming the norm, with investment logic breaking down in search of new patterns.
Dataization and intelligence will be certain investment opportunities in China's next decade. Industrial digitization has become the best response practice for China, and the healthcare industry is no exception. With the gradual improvement of public health and medical information system construction in China, the healthcare industry is undergoing a development transformation from medical informatization to medical service digitization and then to medical intelligence, ultimately aiming to establish a value-oriented healthcare system.
The development of biotech companies cannot do without capital support.
Over the past decade-plus, the development of Chinese biotech companies has essentially been like crossing a river by feeling for the stones. The rapid market explosion started with2018Released by the Hong Kong Stock Exchange18Achapter, inBiotechEnterprise as an example,18Second half of the year21First half of the yearBiotechCompanies conduct intensive operationsIPO listingHowever, a more rough estimate can better explain the current situation faced by biotech companies in the capital market: oneBiotechIt takes an average of two years for a company to go from listing on the Hong Kong Stock Exchange to the launch of its first product; it takes an average of3 - 5year; currently exceeds80%ofBiotechListed companies are still in a state of loss. In other words, a large number of listed and pre-listed companies still have a long way to go before becoming giants in biotechnology.
Capital investment is an indispensable and important factor in driving the growth of biotech companies, and it is crucial for promoting research and development and accelerating business success in the life sciences industry.
since2022Since the first half of the year, there have been certain fluctuations in global and Chinese capital markets. As of2022year8month30day32Hong Kong stocks18AAmong unprofitable biopharmaceutical companies25The company released its semi-annual report, according to2022The level of 'three expenses' disclosed in the interim report, as well as the total amount of cash and cash equivalents currently held by the enterprise25There may be10Enterprises cannot sustain2year, but also5Enterprises can maintain5For more than a year. Some companies have even had to consider shutting down some promising pipelines and even selling off their core products.
According to Frost & Sullivan(shenzhen)Cloud technology data shows,2022Looking at the data on price changes from the lowest price this year to now, biotech-BOverall increase of about34.54%, increase or decrease in priceTop 15The overall enterprise price rose by about54.83%The rebound strength is acceptable; looking at the cumulative rise and fall data since listing, biotech-BOverall decline37.33%IncreaseTop 15The overall stock market fell28.4%The biotechnology industry has indeed seen some market capitalization consolidation, and overly high market cap values are under pressure for adjustment.
Facing the capital winter, the common 'uncertainty' in the capital market, and the inevitable cyclical nature of the industry, if one wants to find more certain investment opportunities in the biopharmaceutical field, it is necessary to conduct long-term and continuous in-depth research on technological trends, policy changes, and industry dynamics in the biotechnology sector. Only by doing so can one keenly capture market fluctuations and provide profound insights for partners.
TIM——New investment concepts and methodologies
In the face of the current market environment and challenges, new investments will become the development direction for biotech companies' investment and financing.
According to the report of the National Bureau of Statistics, last year China's total R&D investment was2.8trillion yuan, accounting forGDPrecent2.5%It firmly ranks as the world's second-largest spender on research and development funding. According to reports from the World Intellectual Property Organization, whether it is the global innovation index or the intensity of R&D expenditure, China has ranked globally as12,13The name exceeds that of innovative countries such as France and the Netherlands. With the country's high emphasis on innovation and technology, there is enormous long-term growth potential and investment opportunity for Chinese science and technology innovation enterprises.
Frost & Sullivan, together with representatives from all sectors, has launched a three-dimensional, multi-dimensional spatial point cloud-based service system -TIM（Total Investment Management), namely 'All-region Investment Management', is different from the classic investment model of 'fundraising, investment, management, and exit' in the past. All-region Investment Management is committed to creating an ecological service system covering the entire life cycle and industrial chain of enterprises. It integrates a series of service capabilities through internalization and linkage within the system, including enterprise management, regulatory communication, industry development trend analysis, market and strategic planning, brand value empowerment, etc., to provide enterprises with better investment management services in all aspects.
In order to fully tap into the growth potential of biotech companies and accelerate their growth rate, Frost & Sullivan has specially invited professionals from various institutions including industry, academia, research, and investment sectors. It is hoped that through joint efforts with all sectors of society, collaborative cooperation can be achieved. Adhering to the concept of 'many hands make light work', we aim to achieve high-level synergy among all stakeholders, providing integrated service solutions for corporate development. Together, we aim to create an upgraded version of the classic investment model of "fund raising, investment management, and asset disposal".
Frost & Sullivan and LeadLeo have nearly500The human analyst team at Frost & Sullivan has long been committed to in-depth industry and corporate original research. Frost & Sullivan has a global presence of over60The industry's most comprehensive database accumulated over the years is included in the reports of LeadLeo, one of the world's largest financial market data and infrastructure providers, with precise access.190country4More than 10,000 institutions,40For users of the Ten-thousand-Dollar Professional Finance platform, seamless integration is available, building a bridge between both the supply and demand sides of investment and financing.
I believe that by working together, each fulfilling their role, we can meticulously craft and long-term implement pan-region investment management to help biotech companies achieve growth. By empowering the transformation and upgrading of the biotech industry through innovation and technology, we can cultivate leading Chinese entrepreneurs and ultimately promote the economic and social development of China.
LeadLeo —— Making professionalism even more professional
LeadLeo Information Technology Nanjing Co., Ltd., abbreviated as 'LeadLeo' in Chinese, is the abbreviation for 'Investment Report'. was officially established2018In [year], it was a leading domestic research project on industry and enterprises Original content platform and provider of innovative professional knowledge and research services.
LeadLeo creates “ABCK"Innovating business models",A"Use it AIEmpowered by AI algorithms Knowledge Management and Research AssistanceSaaSsystem, Intelligent content creation assistance reduces analysts' time costs. Significantly improve efficiency and quality; “B"that is," Big Data, leveraging big data A database of research elements for millions of enterprises; "C"that is," BlockchainUsing blockchain technology and solid data traceability, Build DataIP addressEnsure originality, accuracy, and authenticity; “K"that is," KaaS,Knowledge is a service. Empowering the government with knowledge, so that Knowledge revitalizes industries, and knowledge empowers enterprises.
LeadLeo Education, based on basic research methods and industry analysis systems, combines practical experience in finance, investment, consulting, and other fields to create LeadLeo Classroom ™s online video courses. LeadLeo's research and analysis training, including practical courses for analysts at all levels, with three progressive stages. It integrates with LeadLeo's intelligent research assistance system. Help students at different levels and backgrounds improve their research skills effectively.rise. LeadLeo Education hopes to help more graduates and job seekers acquire the foundational skills needed to enter the workplace through research skills training, thereby enhancing their overall competitiveness and enabling them to enter finance, In industries such as investment and consulting, it empowers national pre-employment education and innovation and entrepreneurship, continuously supplying high-quality research talents to the business community.
This year, the number of fresh university graduates in our country has exceeded one million for the first time, setting new records in both scale and increment. Moreover, amidst the 'mass entrepreneurship and innovation' craze, more and more college students are engaging in entrepreneurial practices. However, they also face issues such as financing difficulties, lack of experience, and inadequate services. They need professional institutions to facilitate their career selection, employment, entrepreneurship, and innovation.
since2021Since the second half of last year, LeadLeo Education has joined hands with Frost & Sullivan to successively establish partnerships with Fudan University School of Management, Shanghai Jiao Tong University Advanced Finance Institute, Wenzhou University, Sichuan University, and Shanghai Luson Hotel Management. The college has carried out cooperation with other institutions and received unanimous praise from students participating in the university courses.
Frost & Sullivan—— Growth Sci-tech innovation Leadership
Achieving growth is the top priority for corporate development, while innovation and entrepreneurship are the core driving forces. Becoming a market leader is a lofty goal for companies to ensure their long-term sustainability. 'New investments' refer to those made in companies that have already achieved or are expected to demonstrate growth, innovation, and leadership in the future. The Frost & Sullivan Summit integrates professional resources, a pool of high-quality targets, capital pools, and expert teams in growth and technology innovation. It deeply empowers practitioners of 'new investment', helping enterprises achieve growth, enabling industrial transformation and upgrading through technology innovation, cultivating leading Chinese entrepreneurs, and ultimately promoting China's economic and social development.
The Frost & Sullivan Summit is attended by more than20Countries and regions, with nearly30With its 10-year history of hosting, it has successfully attracted the world1000Strong participation from leading companies, top domestic and international investment institutions, and other leading enterprises helps them identify opportunities, accelerate growth, innovate continuously, and gain a leadership position in an increasingly complex and dynamic world. The Frost & Sullivan Summit has been held since2008Since its inception in China last year, the event has successfully held sixteen sessions domestically. It has become an important platform for outstanding domestic enterprises, academic institutions, investment experts, and regulatory authorities to exchange successful experiences and jointly explore development directions. It is also an important window for the world to understand China's most cutting-edge development trends.
Frost & Sullivan can assist enterprises in writing in-depth articles and industry whitepapers, as well as conducting multi-channel dissemination. For example, it was established last year60On the occasion of its 10th anniversary, Frost & Sullivan has released a series of significant research findings, including the globally published 'Leading Global Growth60'Technology Leadership in China', 'Global Technology and Application Trends: A Forward-looking Perspective', and the report 'China's Future' jointly released by Frost & Sullivan China and LeadLeo Research Institute50White Paper on Industry Trends for 2021'; another example is the 'Hong Kong Stock Market18AThe 'Biotech Tech Companies Issue Investment Prospectus' is a thematic and panoramic investment report that covers all aspects of the listed healthcare activities in Hong Kong, especially18AThe chapter on listed companies' listing and (subsequent financing) has made a systematic summary, which has received an excellent response within the industry.
since2018Since the beginning of this year, Frost & Sullivan has also successively released multiple white papers covering the biotechnology sector, including cell and gene therapies, oncolytic viruses, ophthalmic treatment drugs, etc. This has enabled them to deeply participate in the research and promotion of various sub-industries, providing important reference perspectives for market investors.
In the future, Frost & Sullivan looks forward to collaborating with you to delve into new trends in biotech investment and financing, identify cutting-edge investment opportunities, and explore the successful paths of biotech companies in the capital market.
